NEW YORK (GenomeWeb News) – A grant and license agreement involving the UK’s Wellcome Trust, the Belgian company Galapagos, and the European Molecular Biology Laboratory's European Bioinformatics Institute will open up the rights to databases held by Galapagos division BioFocus DPI for use by public research communities.
Â
EMBL-EBI will use a Wellcome Trust grant of £4.7 million ($9.4 million) to support the transfer of a collection of information on drug properties and a set of Galapagos’ drug-like small molecules to the Institute. EMBL-EBI will incorporate the data into its collection of open-access resources for use in biomedical research.
Â
Galapagos will receive £1.4 million for the data, which it previously offered for license through its BioFocus DPI service division.
Â
The Galapagos databases covered under the agreement are DrugStore, StARLITe, Strudle, Kinase SARfari, and GPCR SARfari.
Â
The agreement does not include the StarDrop software platform, which BioFocus DPI will continue to offer.
Â
"The scientific community worldwide will greatly benefit from the access to these data for aiding predictive drug discovery," Galapagos CEO Onno van de Stolpe said in a statement.